Official UK procurement notice
NP39726 Generic and Biosimilar Cancer Medicines
Authority: The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
What is being bought36 lots · detail below
Published requirement descriptionSupply of Generic and Biosimilar Cancer Medicines to NHS Scotland.
CPV: Pharmaceutical products
How this framework works
From the published notice- Framework period
- 2 yrs from 1 Feb 2027
Lots and requirements (36)Procurement structure
25 of 36 loaded on this pageShowing the first 25 of 36 published lots; the full list is in the JSON and Markdown mirrors of this notice. 36 lots · all with a published value · evaluation weights differ by lot.
Lot #1Bendamustine powder for solution for infusion vialsRenewalPublished value£169,388
Supply of Lot 1 Bendamustine powder for solution for infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #2Capecitabine tabletsRenewalPublished value£590,765
Supply of Capecitabine tablets to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #3Carboplatin solution for infusion vialsRenewalPublished value£3,480,542
Supply of Carboplatin solution for infusion vials to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier framework agreement to a maximum of three (3) Framework Participants. Full details of Goods and volumes can be found within the ITT documents.
Lot #4Cisplatin solution for infusion vialsRenewalPublished value£1,008,289
Supply of Cisplatin solution for infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #5Cyclophosphamide powder for solution for injection vialsRenewalPublished value£338,258
Supply of Cyclophosphamide powder for solution for injection vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #6Cytarabine solution for injection vialsRenewalPublished value£122,307
Supply of Cytarabine solution for injection vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #7Dacarbazine powder for solution for injection/infusion vialsRenewalPublished value£250,217
Supply of Dacarbazine powder for solution for injection/infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #8Disodium folinate solution for injection vialsRenewalPublished value£283,496
Supply of Disodium folinate solution for injection vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #9Docetaxel solution for infusion vialsRenewalPublished value£808,420
Supply of Docetaxel solution for infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #10Doxorubicin solution for injection vialsRenewalPublished value£277,294
Supply of Doxorubicin solution for injection vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #11Fluorouracil 25mg/ml solution for injection/infusion vialsRenewalPublished value£231,402
Supply of Fluorouracil 25mg/ml solution for injection/infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #12Fluorouracil 50mg/ml solution for injection/infusion vialsRenewalPublished value£1,432,949
Supply of Fluorouracil 50mg/ml solution for injection/infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #13Gemcitabine 38mg/ml solution for infusion vialsRenewalPublished value£310,860
Supply of Gemcitabine 38mg/ml solution for infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier. Full details of Goods and volumes can be found within the ITT documents.
Lot #14Gemcitabine 100mg/ml solution for infusion vialsRenewalPublished value£313,655
Supply of Gemcitabine 100mg/ml solution for infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #15Ifosfamide powder for solution for injection vialsRenewalPublished value£1,759,061
Supply of Ifosfamide powder for solution for injection vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #16Irinotecan solution for infusion vialsRenewalPublished value£751,953
Supply of Irinotecan solution for infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #17Methotrexate solution for injection/infusion vialsRenewalPublished value£490,564
Supply of Methotrexate solution for injection/infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #18Oxaliplatin solution for infusion vialsRenewalPublished value£349,538
Supply of Oxaliplatin solution for infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #19Paclitaxel solution for infusion vialsRenewalPublished value£2,541,766
Supply of Paclitaxel solution for infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #20Temozolomide capsulesRenewalPublished value£257,799
Supply of Temozolomide capsules to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #21Vincristine solution for injection vialsRenewalPublished value£91,122
Supply of Vincristine solution for injection vials to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier framework agreement to a maximum of three (3) Framework Participants. Full details of Goods and volumes can be found within the ITT documents.
Lot #22Vinorelbine solution for infusion vialsRenewalPublished value£24,630
Supply of Vinorelbine solution for infusion vials to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #23Aprepitant capsulesRenewalPublished value£873,964
Supply of Aprepitant capsules to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #24Octreotide solution for injection ampoulesRenewalPublished value£897,199
Supply of Octreotide solution for injection ampoules to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
Lot #25Filgrastim solution for injection pre-filled syringesRenewalPublished value£4,796,431
Supply of Filgrastim solution for injection pre-filled syringes to NHS Scotland. The Authority intends to award this Lot as a single supplier framework agreement. Full details of Goods and volumes can be found within the ITT documents.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Lots publish different evaluation splits; there is no single procedure weighting.
24 more lots publish their own split on the notice.
- Suitability
Economic operators may be excluded from this competition if they are in breach of any situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015
- Technical & professional ability
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB, or PLPI number) that has been approved by the MHRA for all tendered Medicines by the start date of the Framework Agreement.
(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design.
(d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond.
Minimum: (a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB, PLPI number) that has been approved by the MHRA for all tendered Medicines by the start date of the Framework Agreement should be included in the Qualification Envelope of the ITT under the…
- Price carries 95 points on every lot: a 10% discount moves about 9.5 points.
- “NP39726 Generic and Biosimilar Cancer Medicines” is a framework: the contest is a place on its panel, not a single contract.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Closed
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 24 Jul 2026, 16:59 BST
- Last source update
- 30 Jul 2026, 15:49 BST
- Award evaluation window
- 26 Aug 2026 – …
- FTS notice number
2026/S 000-072326- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-06d3b5Find a Tender
- Electronic trading
- e-invoicing allowed · electronic ordering · electronic payment
- Review procedure
The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operators was unsuccessful. The notification will incorporate a ‘standstill period’ of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority dispatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued, or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.
Publisher note: The estimated values referred to in Section II.1.5 and within all Lots covers the twenty four(24) month contract duration and the twenty (24) month extension period of the framework agreement. The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 32105. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343 A sub-contract clause has been included in this contract. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363 Community benefits are included in this requirement. For more information see: https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-procurement/ A summary of the expected community benefits has been provided as follows: It is a mandatory requirement that potential framework participants agree to support the concept, provision, and ongoing development of community benefits provision in relation to this framework. Potential framework participants are required to agree to this mandatory requirement. They are also requested to provide a summary of the community benefits that have recently been delivered within Scotland, if at all, and what impact and outcomes these have achieved. Potential framework participants are required to summarise any proposed community benefits that will be developed and delivered as part of this framework if successful or, alternatively, potential framework participants confirm that they will engage with the NHS Scotland’s Community Benefits Gateway (CBG). This gateway, developed through requests from suppliers seeking opportunities to support the delivery of community benefits within the contracting region, provides information on community benefit opportunities. The CBG is a free and easy to use online service that connects NHS Scotland suppliers with third sector community organisations within Scotland and will be used for tracking and reporting and is an approved compliant route to the realisation of community benefits. For further information please visit NHSS Community Benefit Gateway (https://www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-benefit-gateway/). (SC Ref:838357)
How it was run
Official notice- Appointment period ends
- 1 Sept 2026, 12:00 BST
- Submission channel
- {"electronicSubmission"}
- Accepted languages
- en
- Bid validity
- 90 days from the deadline
- Bids opened
- 26 Aug 2026, 12:00 BST
Timeline
30 Jul 2026 → 1 Feb 2027 · 4 dates- Notice published84 days ago30 Jul 2026, 15:49 BST
- Bids opened57 days ago26 Aug 2026, 12:00 BST
- Admission / appointment period ends51 days ago · period end, not a bid countdown1 Sept 2026, 12:00 BST
- Today22 Oct 2026
- Contract startsin 101 days1 Feb 2027
Notice history
1 event · 2 releases on Find a Tender- Deadline moved to 1 Sept 2026, 12:00 BST30 Jul 2026, 15:49 BST+6 days · was 26 Aug 2026, 12:00 BST
Published amendments (1 · 1 deadline change)
| When | What | Before | After | Shift |
|---|---|---|---|---|
| — | DeadlineTime limit · IV.2.2 | 26 Aug 2026 | 1 Sept 2026 | +6 d |
| — | Bid openingConditions for opening of tenders · IV.2.7 | 26 Aug 2026 | 1 Sept 2026 | +6 d |
Delay to publishing ITT requiring extension to the ITT deadline to compensate.
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Sheriff Court HouseReview body
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.